Login / Signup

Optimising infliximab induction dosing for patients with ulcerative colitis.

Erwin DreesenRuben FaelensGert Van AsscheMarc FerranteSéverine VermeireAnn GilsThomas Bouillon
Published in: British journal of clinical pharmacology (2019)
TDM-based dose individualisation targeting CAUCendoscopy has the potential to improve the effectiveness of infliximab during induction therapy.
Keyphrases
  • ulcerative colitis
  • randomized controlled trial
  • systematic review
  • cancer therapy
  • stem cells
  • human health
  • risk assessment
  • cell therapy
  • bone marrow